STOCK TITAN

Obsidian Therapeutics corrects CEO option to 678,477

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4/A

Rhea-AI Filing Summary

Obsidian Therapeutics, Inc. (OBX) reported that its Chief Executive Officer, Madan Jagasia, received an option award on August 3, 2026, covering 678,477 shares of common stock, correcting the previously reported 37,653 shares. The option has a $12 per-share exercise price and expires August 2, 2036. It vests in 16 equal quarterly installments following the grant date, subject to continued service on each vesting date.

Insider Jagasia Madan
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F1 678,477 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 678,477 options (Direct)
Footnotes (1)
  1. F1. The shares underlying this option shall vest and become exercisable in sixteen (16) equal quarterly installments following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Shares underlying option 678,477 shares Option award granted August 3, 2026
Exercise price $12 per share Option award granted August 3, 2026
Vesting installments 16 equal quarterly installments Following the grant date, subject to continued service on each vesting date
Expiration date August 2, 2036 Option award
Previously reported option shares 37,653 shares Corrected by the amendment to 678,477 shares
vest technical
"shares underlying this option shall vest"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercisable technical
"vest and become exercisable in sixteen equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option did OBX CEO Madan Jagasia receive?

Madan Jagasia received an option covering 678,477 shares of Obsidian Therapeutics common stock on August 3, 2026, with a $12 per-share exercise price. It vests in 16 equal quarterly installments, subject to continued service on each vesting date, and expires August 2, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Jagasia Madan

(Last)(First)(Middle)
C/O OBSIDIAN THERAPEUTICS, INC.
1030 MASSACHUSETTS AVE

(Street)
CAMBRIDGE MASSACHUSETTS 02138

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Obsidian Therapeutics, Inc. [ OBX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
08/05/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1208/03/2026A678,477 (1)08/02/2036Common Stock678,477$0678,477D
Explanation of Responses:
1. The shares underlying this option shall vest and become exercisable in sixteen (16) equal quarterly installments following the grant date, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Remarks:
This amendment to the Form 4 filed on August 5, 2026 corrects the number of shares of Common Stock underlying the option granted to the Reporting Person on August 3, 2026 and the related vesting terms. The option covers 678,477 shares of Common Stock, rather than the 37,653 shares previously reported, and the correct vesting terms are set forth in footnote (1) above.
/s/ Gabriela Morales-Rivera, Attorney-in-Fact11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading